Cargando…
Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study
Patients undergoing hemodialysis with iron deficiency anemia (IDA) receiving treatment with erythropoiesis-stimulating agents (ESAs) who were intolerant or non-responsive to intravenous (i.v.) ferric gluconate (FG) (hemoglobin; Hb values < 10.5 g/dL or increase in <1 g/dL) or % transferrin sat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506237/ https://www.ncbi.nlm.nih.gov/pubmed/36142929 http://dx.doi.org/10.3390/jcm11185284 |
_version_ | 1784796673164181504 |
---|---|
author | Rosati, Alberto Conti, Paolo Berto, Patrizia Molinaro, Sabrina Baldini, Federica Egan, Colin Gerard Panichi, Vincenzo |
author_facet | Rosati, Alberto Conti, Paolo Berto, Patrizia Molinaro, Sabrina Baldini, Federica Egan, Colin Gerard Panichi, Vincenzo |
author_sort | Rosati, Alberto |
collection | PubMed |
description | Patients undergoing hemodialysis with iron deficiency anemia (IDA) receiving treatment with erythropoiesis-stimulating agents (ESAs) who were intolerant or non-responsive to intravenous (i.v.) ferric gluconate (FG) (hemoglobin; Hb values < 10.5 g/dL or increase in <1 g/dL) or % transferrin saturation; TSAT of <20%) in the previous 6 months were switched to i.v. ferric carboxymaltose (FCM). Changes in iron status parameters, economic and safety measures were also assessed. Seventy-seven hemodialysis patients aged 68 ± 15 years were included. Erythropoietin resistance index decreased from 24.2 ± 14.6 at pre-switch to 20.4 ± 14.6 after 6 months of FCM treatment and Hb levels ≥10.5 g/dL improved from 61% to 75.3% patients (p = 0.042). A 1 g/dL increase in Hb levels was also seen in 26% of patients as well as a 37.7% increase in patients achieving >20% increase in TSAT after FCM. Levels of Hb, TSAT and ferritin parameters increased during FCM treatment with a concomitant decrease in ESA. A mixed-model analysis, which also considered gender, confirmed these trends. Safety variables remained stable, no hypersensitivity reaction was recorded and only one patient reported an adverse event after FCM. FCM treatment was associated with a cost saving of 11.11 EUR/patient/month. These results confirm the efficacy, safety and cost-effectiveness of FCM in correcting IDA in hemodialysis patients. |
format | Online Article Text |
id | pubmed-9506237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95062372022-09-24 Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study Rosati, Alberto Conti, Paolo Berto, Patrizia Molinaro, Sabrina Baldini, Federica Egan, Colin Gerard Panichi, Vincenzo J Clin Med Article Patients undergoing hemodialysis with iron deficiency anemia (IDA) receiving treatment with erythropoiesis-stimulating agents (ESAs) who were intolerant or non-responsive to intravenous (i.v.) ferric gluconate (FG) (hemoglobin; Hb values < 10.5 g/dL or increase in <1 g/dL) or % transferrin saturation; TSAT of <20%) in the previous 6 months were switched to i.v. ferric carboxymaltose (FCM). Changes in iron status parameters, economic and safety measures were also assessed. Seventy-seven hemodialysis patients aged 68 ± 15 years were included. Erythropoietin resistance index decreased from 24.2 ± 14.6 at pre-switch to 20.4 ± 14.6 after 6 months of FCM treatment and Hb levels ≥10.5 g/dL improved from 61% to 75.3% patients (p = 0.042). A 1 g/dL increase in Hb levels was also seen in 26% of patients as well as a 37.7% increase in patients achieving >20% increase in TSAT after FCM. Levels of Hb, TSAT and ferritin parameters increased during FCM treatment with a concomitant decrease in ESA. A mixed-model analysis, which also considered gender, confirmed these trends. Safety variables remained stable, no hypersensitivity reaction was recorded and only one patient reported an adverse event after FCM. FCM treatment was associated with a cost saving of 11.11 EUR/patient/month. These results confirm the efficacy, safety and cost-effectiveness of FCM in correcting IDA in hemodialysis patients. MDPI 2022-09-07 /pmc/articles/PMC9506237/ /pubmed/36142929 http://dx.doi.org/10.3390/jcm11185284 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rosati, Alberto Conti, Paolo Berto, Patrizia Molinaro, Sabrina Baldini, Federica Egan, Colin Gerard Panichi, Vincenzo Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study |
title | Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study |
title_full | Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study |
title_fullStr | Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study |
title_full_unstemmed | Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study |
title_short | Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study |
title_sort | efficacy, safety and pharmacoeconomic analysis of intravenous ferric carboxymaltose in anemic hemodialysis patients unresponsive to ferric gluconate treatment: a multicenter retrospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506237/ https://www.ncbi.nlm.nih.gov/pubmed/36142929 http://dx.doi.org/10.3390/jcm11185284 |
work_keys_str_mv | AT rosatialberto efficacysafetyandpharmacoeconomicanalysisofintravenousferriccarboxymaltoseinanemichemodialysispatientsunresponsivetoferricgluconatetreatmentamulticenterretrospectivestudy AT contipaolo efficacysafetyandpharmacoeconomicanalysisofintravenousferriccarboxymaltoseinanemichemodialysispatientsunresponsivetoferricgluconatetreatmentamulticenterretrospectivestudy AT bertopatrizia efficacysafetyandpharmacoeconomicanalysisofintravenousferriccarboxymaltoseinanemichemodialysispatientsunresponsivetoferricgluconatetreatmentamulticenterretrospectivestudy AT molinarosabrina efficacysafetyandpharmacoeconomicanalysisofintravenousferriccarboxymaltoseinanemichemodialysispatientsunresponsivetoferricgluconatetreatmentamulticenterretrospectivestudy AT baldinifederica efficacysafetyandpharmacoeconomicanalysisofintravenousferriccarboxymaltoseinanemichemodialysispatientsunresponsivetoferricgluconatetreatmentamulticenterretrospectivestudy AT egancolingerard efficacysafetyandpharmacoeconomicanalysisofintravenousferriccarboxymaltoseinanemichemodialysispatientsunresponsivetoferricgluconatetreatmentamulticenterretrospectivestudy AT panichivincenzo efficacysafetyandpharmacoeconomicanalysisofintravenousferriccarboxymaltoseinanemichemodialysispatientsunresponsivetoferricgluconatetreatmentamulticenterretrospectivestudy |